Analysts Offer Insights on Healthcare Companies: Kestra Medical Technologies Ltd. (KMTS) and Milestone Pharmaceuticals (MIST)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kestra Medical Technologies Ltd. (KMTS – Research Report) and Milestone Pharmaceuticals (MIST – Research Report) with bullish sentiments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kestra Medical Technologies Ltd. (KMTS)
In a report released today, Matthew O’Brien from Piper Sandler maintained a Buy rating on Kestra Medical Technologies Ltd., with a price target of $27.00. The company’s shares closed last Tuesday at $16.29.
According to TipRanks.com, O’Brien has 0 stars on 0-5 stars ranking scale with an average return of
Kestra Medical Technologies Ltd. has an analyst consensus of Strong Buy, with a price target consensus of $27.67, implying a 78.2% upside from current levels. In a report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $30.00 price target.
See the top stocks recommended by analysts >>
Milestone Pharmaceuticals (MIST)
In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Milestone Pharmaceuticals, with a price target of $4.00. The company’s shares closed last Tuesday at $1.48.
According to TipRanks.com, Tenthoff has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Milestone Pharmaceuticals is a Moderate Buy with an average price target of $5.00, which is a 252.1% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $5.00 price target.
Read More on KMTS:
